CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, vol.62, no.4, pp.261-271, 2001 (Peer-Reviewed Journal)
Article / Article
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
Science Citation Index Expanded, Scopus
Background: Only 40% to 60% of patients with essential hypertension respond adequately to antihypertensive monotherapy. The combination of an angiotensin-converting enzyme inhibitor and a calcium antagonist, both of which have tissue-protective properties but different mechanisms of action, may lead to an additive antihypertensive effect.